US › Healthcare

India Globalization Capital Inc (IGC)

US · Healthcare · Biotechnology

$0.27-1.33%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$265,000

Revenue YoY

-19.2%

Net profit

$-2.9M

EPS

$-0.03

EPS estimate

$-0.02

Net margin

-1,107.9%

EPS came in at -0.03 against a street estimate of -0.02 — a miss of 50.0%.

Key statistics

Market cap

$29.3M

Forward P/E

0.0

P/B

4.75

Book value

$0.06

EPS (TTM)

$-0.06

52-week high

$0.45

52-week low

$0.24

50-day MA

$0.28

200-day MA

$0.29

Beta

0.49

Analyst view

Analysts rate India Globalization Capital Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.00.

Shareholding

Insiders

13.51%

Institutions

22.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for India Globalization Capital Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.